PMID- 30552862
OWN - NLM
STAT- MEDLINE
DCOM- 20190320
LR  - 20190320
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 44
IP  - 2
DP  - 2019 Apr
TI  - Effects of proton pump inhibitors on severe haematotoxicity induced after first 
      course of pemetrexed/carboplatin combination chemotherapy.
PG  - 276-284
LID - 10.1111/jcpt.12788 [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: Pemetrexed/carboplatin combination chemotherapy has 
      shown efficacy as a first-line treatment for advanced non-small-cell lung cancer. 
      However, severe haematotoxicity is often observed during this combination 
      chemotherapy. Some studies have suggested that concomitant drugs may be the risk 
      factors for severe adverse events. However, those studies identified the 
      predictive risk factors without paying attention to the relative dose intensities 
      (RDIs) of the anticancer drugs. The objective of this study was to clarify the 
      effects of concomitant drugs on the severe haematotoxicity induced by 
      pemetrexed/carboplatin combination chemotherapy using multiple logistic 
      regression analysis incorporating RDIs of the anticancer drugs. METHODS: We 
      retrospectively reviewed the records of 61 patients who had received first-line 
      treatment with this combination chemotherapy at Yamato Municipal Hospital between 
      April 2011 and May 2017. Severe haematotoxicity was defined as grade 3 or 4 
      according to the Common Terminology Criteria for Adverse Events, version 4.0. To 
      clarify the influence of concomitant drugs on haematotoxicity, we performed 
      multiple logistic regression analysis. RESULTS: Among the 61 patients, 18 (29.5%) 
      developed grade 3 or 4 haematotoxicity. Multiple logistic regression analysis 
      showed that body weight <54.5 kg [odds ratio: 5.21, 95% confidence interval (CI): 
      1.17-23.08, P = 0.030], haemoglobin <12.0 g/dL [odds ratio: 7.13, 95% CI: 
      1.54-33.11, P = 0.012], and coadministration of proton pump inhibitors (PPIs) 
      [odds ratio: 5.34, 95% CI: 1.06-26.94, P = 0.042] were significantly associated 
      with severe haematotoxicity in patients receiving pemetrexed/carboplatin 
      combination chemotherapy after adjustment using non-steroidal anti-inflammatory 
      drugs and RDIs of the anticancer drugs. WHAT IS NEW AND CONCLUSION: Multiple 
      logistic regression analysis incorporating RDIs of the anticancer drugs revealed 
      that low baseline body weight, low baseline haemoglobin level, and 
      coadministration of PPIs were the independent risk factors for predicting severe 
      haematotoxicity induced by pemetrexed/carboplatin combination chemotherapy.
CI  - (c) 2018 John Wiley & Sons Ltd.
FAU - Araki, Ryosuke
AU  - Araki R
AD  - Department of Pharmacy, Yamato Municipal Hospital, Kanagawa, Japan.
AD  - Laboratory of Applied Therapeutics, Center for Education & Research on Clinical 
      Pharmacy, Showa Pharmaceutical University, Tokyo, Japan.
FAU - Keira, Takayuki
AU  - Keira T
AD  - Department of Pharmacy, St. Marianna University School of Medicine Hospital, 
      Kanagawa, Japan.
FAU - Masuda, Yutaka
AU  - Masuda Y
AD  - Laboratory of Applied Therapeutics, Center for Education & Research on Clinical 
      Pharmacy, Showa Pharmaceutical University, Tokyo, Japan.
FAU - Tanaka, Tsuneaki
AU  - Tanaka T
AD  - Department of Pharmacy, St. Marianna University School of Medicine Hospital, 
      Kanagawa, Japan.
FAU - Yamada, Hideki
AU  - Yamada H
AD  - Department of Pharmacy, Yamato Municipal Hospital, Kanagawa, Japan.
FAU - Hamamoto, Tomoyuki
AU  - Hamamoto T
AD  - Laboratory of Applied Therapeutics, Center for Education & Research on Clinical 
      Pharmacy, Showa Pharmaceutical University, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20181215
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Hemoglobins)
RN  - 0 (Proton Pump Inhibitors)
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - BG3F62OND5 (Carboplatin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse 
      effects
MH  - Carboplatin/administration & dosage
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - Female
MH  - Hematologic Diseases/*chemically induced/epidemiology
MH  - Hemoglobins/*metabolism
MH  - Humans
MH  - Logistic Models
MH  - Lung Neoplasms/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pemetrexed/administration & dosage
MH  - Proton Pump Inhibitors/*administration & dosage/adverse effects
MH  - Retrospective Studies
MH  - Risk Factors
OTO - NOTNLM
OT  - carboplatin
OT  - concomitant drug
OT  - haematotoxicity
OT  - pemetrexed
OT  - proton pump inhibitor
OT  - relative dose intensity
EDAT- 2018/12/16 06:00
MHDA- 2019/03/21 06:00
CRDT- 2018/12/16 06:00
PHST- 2018/07/03 00:00 [received]
PHST- 2018/10/19 00:00 [revised]
PHST- 2018/11/19 00:00 [accepted]
PHST- 2018/12/16 06:00 [pubmed]
PHST- 2019/03/21 06:00 [medline]
PHST- 2018/12/16 06:00 [entrez]
AID - 10.1111/jcpt.12788 [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2019 Apr;44(2):276-284. doi: 10.1111/jcpt.12788. Epub 2018 Dec 
      15.